GSK sells stake in diagnostics firm to raise $1.7 billion
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has sold its entire remaining stake in Quest Diagnostics, just under 31 million shares. GSK said that it had been considering the move for some time and had decided that now was "a good time to take advantage of favourable market conditions, thereby releasing funds from one of our non-core assets".